Microbial production of thioether-stabilized peptides
PhD ceremony: Ms. A. Kuipers, 16.15 uur, Academiegebouw, Broerstraat 5, Groningen
Thesis: Microbial production of thioether-stabilized peptides
Promotor(s): prof. O.P. Kuipers
Faculty: Mathematics and Natural Sciences
The thesis of Anneke Kuipers describes the successful biological production and secretion of thioether-stabilized therapeutic peptides. The lantibiotic modification- and transport enzymes NisBTC and LtnM2T involved in the synthesis of the lantibiotics nisin and lacticin 3147, respectively, were exploited for the introduction of thioether bridges in nonlantibiotic peptides. Importantly, thioether peptides produced via lantibiotic enzymes contain only one isomer(DL), whereas chemically induced thioether formation can lead to several stereo isomers (i.e. DL, LL, LD and DD). Exploiting the nisin modification enzymes NisB and NisC, we were able to demonstrate for the first time the posttranslational introduction of a thioether bridge in a therapeutic peptide, an analog of angiotensin-(1-7). This therapeutic peptide variant has a significantly improved stability and the effectivity of its interaction with the angiotensin-(1-7) receptor is even enhanced. This cyclized analog of angiotensin-(1-7) is therefore a promising therapeutic peptide candidate for treatment of cardiovascular diseases. Moreover, other therapeutic peptides may be thioether-stabilized, using lantibiotic synthesis enzymes. By stabilization, these therapeutic peptides are less sensitive to proteolytic breakdown and accordingly need less frequent administration and/or in a lower dose. In addition, stabilization may allow oral and pulmonary delivery. These delivery ways are more patient-friendly than injection. While there are hundreds of medically highly important therapeutic peptides, the pharmaceutical market of already a single therapeutic peptide can have a size of over a billion dollar. Consequently, stabilization of already FDA-approved therapeutic peptide hormones and development of new effective stabilized peptides has a tremendous potential.
Last modified: | 13 March 2020 01.16 a.m. |
More news
-
15 April 2025
1.5 million funding from Province of Groningen for innovative technology in the region
The University of Groningen will receive nearly 1.5 million euros in funding from the Province of Groningen to assist entrepreneurial academic researchers in developing innovative ideas into a startup.
-
15 April 2025
Nathalie Katsonis wins Ammodo Science Award 2025
For her pioneering research on molecular systems, Nathalie Katsonis receives the Ammodo Science Award for fundamental research 2025.
-
15 April 2025
Fundamental research with life-size effects
Nathalie Katsonis has won the Ammodo Science Award for Fundamental Research. She develops adaptive molecular materials and studies the chemical origins of life, which in turn yield insights for vaccines and clearing up oil spills at sea.